Endpoint
Clinical pregnancy rate
CAT:outcome/clinical-pregnancy-ratereported in risk ratio
Method
Proportion of participants or treatment cycles with an ultrasound-confirmed intrauterine gestational sac, typically at 6 to 7 weeks, pooled as a risk ratio or odds ratio. The denominator - per woman, per cycle started, or per embryo transfer - is recorded on the edge and materially changes the estimate.
The method is part of the endpoint identity. Studies measuring the same quantity by a different method are held as separate endpoints.
Notes
An ultrasound finding, and it is NOT live birth rate, which is not measured here: it overstates the take-home-baby rate by the whole first-trimester miscarriage fraction, roughly 15 to 25 percent, so substituting one for the other inflates the clinical effect. Confusable also with biochemical pregnancy rate, a serum hCG rise that runs higher still because it includes chemical losses, and with ovulation rate, a necessary precondition that can improve with no change here. Denominator confusion is the second most common error in this literature.
Findings
1 finding from 1 compound, strongest first.
coenzyme Q10 — no detected effect on
LikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull result“No noticeable variations were demonstrated in clinical pregnancy rates (P = 0.888), lower miscarriage rates (p = 0.676), or twin pregnancies (p = 0.792); however, CoQ10 appeared to demonstrate promising outcomes (Table 3).”
Quoted verbatim from Coenzyme Q10 Impact on Ovarian Reserve Measures and the Intra-Cytoplasmic Sperm Injection (ICSI) Outcomes in Women with Poor Ovarian Response: A Randomized Controlled Study.. - Study
- RCT
- Dose
- Coenzyme Q10 200 mg twice daily (Synapse CoQ10 200 mg, Synapse Pharm), started one month before the ICSI cycle and continued through it
- Population
- Women aged 25 to 45 with poor ovarian response by the Bologna criteria undergoing intracytoplasmic sperm injection; secondary endpoint.